AstraZeneca, Daiichi Sankyo’s Enhertu impresses in 'game-changing' study with many cancers: #ASCO23

Lei Lei Wu

News Reporter

CHICAGO — AstraZeneca and Daiichi Sankyo’s Enhertu showed promising efficacy in a range of cancers — particularly gynecologic cancers — that express the biomarker HER2, according to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca, Daiichi Sankyo’s Enhertu impresses in 'game-changing' study with many cancers: #ASCO23

Lei Lei Wu

News Reporter

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

China’s biotech market is staging a comeback that US biotech can only wish for

Genentech vet launches ADC startup with $20M

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

As­traZeneca, Dai­ichi Sankyo’s En­her­tu im­press­es in 'game-chang­ing' study with many can­cers: #AS­CO23

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

AstraZeneca, Daiichi Sankyo’s Enhertu impresses in 'game-changing' study with many cancers: #ASCO23